Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Apogee Therapeutics

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
Apogee Therapeutics Announces Agenda for Virtual R&D Day
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
Apogee Therapeutics to Participate in Upcoming November Investor Conferences
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
Apogee Therapeutics Strengthens Team with Appointments of Industry Leaders to Board of Directors and Management
From Apogee Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.